Clinical trials: Letrozole
Primary Infertility, Secondary Infertility
Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF
The purpose of this study to evaluate a low cost minimal stimulation protocol combined with Intravaginal Culturing, to make IVF affordable and available across the large infertile/subfertile population
- Conditions
- Primary Infertility, Secondary Infertility, Low Responders, Mild to Moderate Male Factor Infertility
- Trial name
- MSP-INVO IVF (NCT01058252)
- Testing
- INVOCell, Letrozole 2.5 mg, recFSH 75 IU, STEP-3: LH Suppression & Monitoring, STEP-4: HCG Timing
- Where
- 2 sites in Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Galaxy Pharma (Pvt) Limited
Healthy
Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women
This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
- Trial name
- LEILA-1 (NCT06315205)
- Testing
- Letrozole LEBE 75 mg, Letrozole LEBE 150 mg, Letrozole LEBE 225 mg
- Where
- Czechia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Healthy
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.
- Trial name
- NCT01375452
- Testing
- Letrozole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)
This is a Phase I, open label, dose escalation study designed to evaluate the pharmacokinetics, safety, and tolerability of single intramuscular injections of Letrozole ISM® at different strengths in voluntary healthy post…
- Trial name
- NCT03401320
- Testing
- Letrozole ISM
- Where
- Czechia
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Healthy
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fed conditions.
- Trial name
- NCT01372982
- Testing
- Letrozole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Breast Cancer
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Letrozole Tablet under fed conditions.
- Trial name
- NCT01367626
- Testing
- letrozole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Breast Cancer
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Letrozole Tablet under fasted conditions.
- Trial name
- NCT01367652
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Healthy
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fed conditions.
- Trial name
- NCT00648154
- Testing
- Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Bioequivalence Study of Letrozole 2.5 mg Tablets
Bioequivalence
- Trial name
- NCT01084499
- Testing
- Femara (Sequence 1), Peratra (Sequence 1), Femara (Sequence 2)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fasting conditions.
- Trial name
- NCT00648063
- Testing
- Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc